September 6, 2007 — A new study using a mouse model of myotonic dystrophy type 1 (DM1) has revealed an early step in the process by which a mutant DM gene leads to cardiac defects. Found in more than ...

Dyne Therapeutics Inc. (NASDAQ: DYN) is one of the best hot stocks to invest in. On October 7, Dyne Therapeutics announced ...

Researchers focused on Myotonic Dystrophy 1 heart problems are testing a novel approach to restore normal function. Myotonic Dystrophy Type 1 (DM1) is the most common adult-onset form of muscular ...

The FDA has granted Fast Track designation to SAR446268 for the treatment of non-congenital myotonic dystrophy type 1.

France: The findings of a new study published in JAMA Cardiology suggest that an electrophysiological study (EPS) provides ...

DM1 primarily affects skeletal and cardiac muscle and is characterized by muscle weakness, difficulty breathing, and cognitive and behavioral impairment. The Food and Drug Administration (FDA) has ...

Myotonic dystrophy type 1 incurs high healthcare costs, driven by age and comorbidities like cardiac and respiratory issues. Early detection and integrated management of multisystemic complications ...

Please provide your email address to receive an email when new articles are posted on . The FDA has granted breakthrough therapy designation to a proprietary oligonucleotide conjugate for the ...

Please provide your email address to receive an email when new articles are posted on . The FDA has granted fast-track designation to an investigational antisense oligonucleotide to treat individuals ...

Dublin, Dec. 18, 2024 (GLOBE NEWSWIRE) -- The "Myotonic Dystrophy - Epidemiology Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. The report delivers an in-depth ...

LONDON, Sept. 15, 2025 /PRNewswire/ -- AMO Pharma Limited ("AMO Pharma"), a privately held clinical-stage specialty biopharmaceutical company focusing on rare genetic disorders with limited or no ...